Get a Paxlovid Prescription Online

Request a Paxlovid assessment now if you are seeking COVID treatment. Message a provider with when symptoms started, your test result and your current medications. The provider checks whether treatment is appropriate and whether you are within the treatment window before prescribing. If you have emergency symptoms, use the emergency-care instructions below instead of waiting for a chat response.

Care starts by chat with a licensed provider. Message us and we will confirm coverage in your state.

How many days do I have to start COVID antivirals?

Five. The FDA label for Paxlovid (nirmatrelvir and ritonavir) says treatment is started as soon as possible after diagnosis and within 5 days of symptom onset [1]. The alternative oral antiviral, molnupiravir, carries the same 5 day limit [4]. That is not a soft guideline. It is the boundary of the population the drugs were actually tested in, and outside it nobody can tell you the medicine still helps.

Which day counts as day one?

The day your symptoms started, not the day your test turned positive [1]. People lose two or three days waiting for a test result, then lose two more waiting for an appointment, and arrive on day six. The sore throat on Monday is day one even if the test line showed up on Wednesday.

Why is the window so tight?

These drugs stop the virus from copying itself, which is useful while it is still multiplying, in the first few days. What lands people in hospital later is mostly the body's own inflammatory response, and an antiviral has little to offer once that has taken over. The pivotal trial reported its headline result in people treated within 3 days of symptom onset [3]. Earlier is genuinely better, not just tidier.

Does everyone with COVID need an antiviral?

No. Paxlovid is indicated for people at high risk of progressing to severe COVID-19, not for everyone with a positive test [1]. If you are young, healthy, vaccinated and have no risk factors, the honest answer is usually rest, fluids and symptom relief. The rest of this page is about telling which group you are in, quickly, because the clock does not pause while you decide.

Photo: Paxlovid packaging by Kches16414, CC BY-SA 4.0. Original photograph.

Who counts as high risk?

The label points prescribers at the CDC list rather than defining risk itself [2]. CDC names age as the strongest single risk factor, with risk rising steeply as age rises, alongside diabetes, obesity, chronic kidney disease, chronic lung disease including COPD and asthma, heart conditions, chronic liver disease, cancer, HIV, transplant, immunosuppressive medication, pregnancy and recent pregnancy, disability including Down syndrome, current or former smoking, and several neurologic and mental health conditions [9]. It is a longer list than most people expect, and plenty of people who assume they do not qualify actually do.

Is there an age limit?

The approved label covers adults [1]. Use in children rests on a separate emergency use authorization, most recently revised in February 2026, which covers patients 12 years and older weighing at least 40 kg who are at high risk [2]. Molnupiravir is authorized for adults 18 and over only, and is explicitly not authorized below 18 because of concerns about bone and cartilage growth [4]. Anyone 18 or under is treated with us only with a parent or guardian's consent, which is covered in getting care for your child online.

How well does Paxlovid actually work?

In the trial that led to approval, unvaccinated high risk adults treated within 3 days of symptom onset had an 89% lower risk of COVID related hospitalization or death by day 28 than those given placebo. In absolute terms that was 0.77% versus 7.01%, and all 13 deaths in the study were in the placebo group [3]. Read that number with its context: the participants were unvaccinated and had no prior infection, so the benefit in a vaccinated person with some immunity is smaller. It is still the most effective outpatient option available.

Why does my medication list matter more than usual here?

Because of the second drug in the box. Ritonavir is there to keep nirmatrelvir at a working level in the blood, and it does that by strongly blocking the liver enzyme CYP3A, which is the same enzyme that clears a large share of everyday medicines. The label carries a boxed warning for exactly this and instructs prescribers to review every medication first [1][2]. The block is not a gentle nudge either. Ritonavir binds the enzyme irreversibly, so the effect outlasts the drug in your bloodstream: pharmacokinetic modelling reported in Clinical Infectious Diseases puts most of the inhibition gone two to three days after the last dose, which is why paused medicines wait that long before restarting [5].

The label's contraindicated list runs to dozens of drugs, and they are not obscure. It includes simvastatin and lovastatin, amiodarone, flecainide, propafenone and quinidine, colchicine, carbamazepine, phenytoin and phenobarbital, rifampin, triazolam and oral midazolam, ergotamine, pimozide and lurasidone, and St. John's Wort [1]. Some of those get held for five days and restarted. Some mean a different antiviral. Either way a person has to look, and looking takes a real medication list rather than a checkbox.

Does my kidney or liver function change the dose?

Yes, which is the other reason a prescriber needs more than a symptom form. With moderate kidney impairment the nirmatrelvir dose is halved to 150 mg twice daily; with severe impairment it becomes 300 mg on day 1 then 150 mg once daily, given after dialysis on dialysis days [1]. Paxlovid is not recommended in severe liver impairment [1]. If you have kidney or liver disease and no recent bloodwork, that is a real gap, and ordering your own blood tests covers how that gets sorted.

What if I cannot take Paxlovid?

There are two fallbacks, and both are genuinely second choices.

• Molnupiravir (Lagevrio). 800 mg every 12 hours for 5 days, adults 18 and over, started within 5 days of symptom onset. It sits under an emergency use authorization rather than full approval, and that authorization limits it to people for whom other FDA approved or authorized options are not accessible or clinically appropriate [4]. Its trial showed hospitalization or death in 6.8% on treatment versus 9.7% on placebo, a much smaller effect than nirmatrelvir's [6]. It is not recommended in pregnancy, and people who could become pregnant are advised to use reliable contraception for 4 days after the last dose [4].
• Remdesivir. A 3 day intravenous course, which in outpatients starting within 7 days of symptom onset cut hospitalization or death by 87% [7]. The longer window is real and useful. The catch is that it is an infusion given on three consecutive days, so it needs an infusion centre or hospital outpatient service, not a prescription.

I am on day six. Is it too late?

For the oral antivirals, yes, the labelled window has closed [1][4]. Remdesivir's 7 day outpatient window may still be open, which is worth asking about if you are high risk [7]. Beyond that, care shifts to managing symptoms and watching for the signs below. It is a frustrating answer, and it is the reason the first section of this page is about counting days rather than about drugs.

Does Paxlovid cause COVID rebound?

Rebound, meaning symptoms or test positivity returning after they had settled, is real. Whether the drug causes it is less clear than the headlines suggested. A prospective study that followed both treated and untreated people with regular antigen testing found viral rebound in 14.2% of treated participants and 9.3% of untreated controls, with symptom rebound in 18.9% versus 7.0% [8]. It happened in both groups, the numbers were small, and the authors called for larger studies. The honest reading: expect it as a possibility, do not treat it as a reason to skip treatment, and if it happens, isolate again and tell your provider.

Can I take an antiviral just in case I was exposed?

No. Paxlovid is not authorized or approved for pre-exposure or post-exposure prevention of COVID-19 [1][2]. It treats a confirmed infection in someone at high risk. Nothing here replaces vaccination for prevention.

When should I stop reading and get emergency care?

Trouble breathing or breathlessness at rest, chest pain or pressure, new confusion, trouble staying awake, blue or grey lips or face, or an inability to keep fluids down. Those are emergency department problems, right now, not chat problems. The same instinct applies to the other time-critical conditions we cover, such as the shingles antiviral window, where one presentation is an emergency rather than a prescription.

How Well Revolution handles a five day clock

A time-critical window is a bad fit for a booking system. Ours is a chat, so you can start it the hour your symptoms start rather than the day an appointment opens up.

• Same day, no appointment. Message us, answer the questions, and a licensed provider reviews it the same day.
• Your full medication list gets read by a person. Given the boxed warning, this is the part that matters most, and it is why we ask for every prescription, over the counter product and supplement, including anything you take occasionally [1][5].
• We tell you when the answer is no. If you are outside the window, outside the risk criteria, or on a drug that makes Paxlovid unsafe, you get that answer plainly along with what to do instead.
• Unlimited follow-up. Rebound, side effects, or a symptom that turns a corner: message the same thread, no new visit.
• Coverage. We are licensed in a number of states. Message us and we will confirm coverage in yours.

If you want the background on what makes an online prescription legitimate in the first place, that is covered in what makes a US prescription valid.

What it costs with Well Revolution

$50 for a prescription. If approved, you will receive a prescription for an antiviral if you qualify and 30 days of support. We are there for those 30 days for follow-up, interpretation, referrals, and treatment if needed. Perfect for a single episode of care.

Or $90 for the Unlimited Membership. If approved, you will receive 3 months of care with 7 days a week support, plus unlimited prescriptions, lab tests, imaging orders, letters and referrals with same day care, cancel anytime, no fees. Perfect for established patients looking for full care.

Getting started with Well Revolution

Care is chat-based with a licensed provider, same day, no appointment needed. Message us with when symptoms started, your test result, and your current medications, tell us where you are, and we will confirm coverage in your state and whether you are inside the treatment window.

References

• [1] Pfizer. PAXLOVID (nirmatrelvir tablets; ritonavir tablets) prescribing information. DailyMed, 2026. dailymed.nlm.nih.gov
• [2] US Food and Drug Administration. Fact Sheet for Healthcare Providers: Emergency Use Authorization for PAXLOVID, revised 02/2026. fda.gov
• [3] Hammond J, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med, 2022. pubmed.ncbi.nlm.nih.gov/35172054
• [4] Merck Sharp and Dohme. LAGEVRIO (molnupiravir) capsules, emergency use authorization fact sheet. DailyMed, 2026. dailymed.nlm.nih.gov
• [5] Kuriakose S, Tseng A, Boyd S, et al. International Collaboration to Develop and Harmonize Drug Interaction Guidance for Nirmatrelvir/Ritonavir During COVID-19. Clinical Infectious Diseases, 2026. pubmed.ncbi.nlm.nih.gov/41178257
• [6] Jayk Bernal A, et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med, 2022. pubmed.ncbi.nlm.nih.gov/34914868
• [7] Gottlieb RL, et al. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. N Engl J Med, 2022. pubmed.ncbi.nlm.nih.gov/34937145
• [8] Pandit JA, et al. The Coronavirus Disease 2019 Rebound Study: viral and symptom rebound in participants treated with nirmatrelvir plus ritonavir versus untreated controls. Clin Infect Dis, 2023. pubmed.ncbi.nlm.nih.gov/36810665
• [9] Centers for Disease Control and Prevention. Underlying Conditions and the Higher Risk for Severe COVID-19. Confirmed as of 2026-09-03. cdc.gov

Reviewed by PA Michael Rubio, US Medical Director